Document is current
Any future updates will be listed below
-
Authors
Genitsaridi, Eleni https://orcid.org/0000-0002-7752-4692
Papoutselou, Efstratia https://orcid.org/0000-0002-1482-9501
Campbell-Bell, Cherith M. https://orcid.org/0000-0002-7094-6075
Abbas, Leila https://orcid.org/0009-0009-7013-5924
Haines, Rachel https://orcid.org/0000-0001-7924-0602
Hartley, Douglas E. H. https://orcid.org/0000-0001-9803-4169
Rivolta, Marcelo N. https://orcid.org/0000-0003-4178-8570
- License Information
-
More Information
Article History
Received: 4 September 2025
Accepted: 8 February 2026
First Online: 25 February 2026
Declarations
:
: Artificial Intelligence (AI) assisted tools (Microsoft Copilot; Generative Pre-trained Transformer-based text-refinement functions; Microsoft Corporation; used intermittently between August 2025 and January 2026) were employed to improve readability and ensure a cohesive writing style throughout the manuscript. These tools were used solely for grammar, spelling, punctuation, clarity, and style refinement, and for generating brief summaries of author-provided text. The AI tools did not generate scientific content, perform data analysis, or create figures or artwork. All authors reviewed and approved the AI-refined text and accept full responsibility for the integrity and accuracy of the final manuscript.
: All authors are employees of and/or financially supported by Rinri Therapeutics Ltd. Marcelo Rivolta is the Founder, Director, and Chief Scientific Officer and Douglas Hartley is the Chief Medical Officer of Rinri Therapeutics Ltd.
